The global viral vectors based gene therapy for non-human primates market size is calculated at USD 1.5 billion in 2025 and is forecasted to reach around USD 5.46 billion by 2034, accelerating at a CAGR of 15.44% from 2025 to 2034. The North America market size surpassed USD 585.00 million in 2024 and is expanding at a CAGR of 15.56% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Viral Vectors-Based Gene Therapy for Non-Human Primates Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Viral Vectors-Based Gene Therapy for Non-Human Primates Market, by Vector Type
8.1.1. Adeno-Associated Virus (AAV)
8.1.1.1. Market Revenue and Forecast
8.1.2. Lentiviral Vectors
8.1.2.1. Market Revenue and Forecast
8.1.3. Adenovirus (~12%)
8.1.3.1. Market Revenue and Forecast
8.1.4. Herpes Simplex Virus (HSV) (~6%)
8.1.4.1. Market Revenue and Forecast
8.1.5. Other (e.g., Vaccinia, Retrovirus) (~7%)
8.1.5.1. Market Revenue and Forecast
9.1. Viral Vectors-Based Gene Therapy for Non-Human Primates Market, by Application
9.1.1. CNS & Neurological Disease Models
9.1.1.1. Market Revenue and Forecast
9.1.2. Ophthalmology (Retinal Gene Therapy)
9.1.2.1. Market Revenue and Forecast
9.1.3. Cardiovascular / Muscle Gene Delivery
9.1.3.1. Market Revenue and Forecast
9.1.4. Liver-Directed Gene Therapy
9.1.4.1. Market Revenue and Forecast
9.1.5. Oncology (oncolytic viruses, immunotherapy vectors)
9.1.5.1. Market Revenue and Forecast
9.1.6. Metabolic Disease Models
9.1.6.1. Market Revenue and Forecast
10.1. Viral Vectors-Based Gene Therapy for Non-Human Primates Market, by Service Type
10.1.1. Vector Manufacturing & GMP-grade Supply
10.1.1.1. Market Revenue and Forecast
10.1.2. GLP Toxicology & Biodistribution Studies
10.1.2.1. Market Revenue and Forecast
10.1.3. In Vivo Dosing & Surgical Delivery
10.1.3.1. Market Revenue and Forecast
10.1.4. Immunogenicity & Safety Assays
10.1.4.1. Market Revenue and Forecast
10.1.5. PK/PD & Transgene Expression Analytics
10.1.5.1. Market Revenue and Forecast
11.1. Viral Vectors-Based Gene Therapy for Non-Human Primates Market, by End User
11.1.1. Biopharma & Gene Therapy Companies
11.1.1.1. Market Revenue and Forecast
11.1.2. Academic & Non-Profit Research Institutes
11.1.2.1. Market Revenue and Forecast
11.1.3. Preclinical CROs
11.1.3.1. Market Revenue and Forecast
11.1.4. Government & Safety-Regulatory Labs
11.1.4.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Vector Type
12.1.2. Market Revenue and Forecast, by Application
12.1.3. Market Revenue and Forecast, by Service Type
12.1.4. Market Revenue and Forecast, by End User
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Vector Type
12.1.5.2. Market Revenue and Forecast, by Application
12.1.5.3. Market Revenue and Forecast, by Service Type
12.1.5.4. Market Revenue and Forecast, by End User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Vector Type
12.1.6.2. Market Revenue and Forecast, by Application
12.1.6.3. Market Revenue and Forecast, by Service Type
12.1.6.4. Market Revenue and Forecast, by End User
12.2. Europe
12.2.1. Market Revenue and Forecast, by Vector Type
12.2.2. Market Revenue and Forecast, by Application
12.2.3. Market Revenue and Forecast, by Service Type
12.2.4. Market Revenue and Forecast, by End User
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Vector Type
12.2.5.2. Market Revenue and Forecast, by Application
12.2.5.3. Market Revenue and Forecast, by Service Type
12.2.5.4. Market Revenue and Forecast, by End User
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Vector Type
12.2.6.2. Market Revenue and Forecast, by Application
12.2.6.3. Market Revenue and Forecast, by Service Type
12.2.6.4. Market Revenue and Forecast, by End User
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Vector Type
12.2.7.2. Market Revenue and Forecast, by Application
12.2.7.3. Market Revenue and Forecast, by Service Type
12.2.7.4. Market Revenue and Forecast, by End User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Vector Type
12.2.8.2. Market Revenue and Forecast, by Application
12.2.8.3. Market Revenue and Forecast, by Service Type
12.2.8.4. Market Revenue and Forecast, by End User
12.3. APAC
12.3.1. Market Revenue and Forecast, by Vector Type
12.3.2. Market Revenue and Forecast, by Application
12.3.3. Market Revenue and Forecast, by Service Type
12.3.4. Market Revenue and Forecast, by End User
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Vector Type
12.3.5.2. Market Revenue and Forecast, by Application
12.3.5.3. Market Revenue and Forecast, by Service Type
12.3.5.4. Market Revenue and Forecast, by End User
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Vector Type
12.3.6.2. Market Revenue and Forecast, by Application
12.3.6.3. Market Revenue and Forecast, by Service Type
12.3.6.4. Market Revenue and Forecast, by End User
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Vector Type
12.3.7.2. Market Revenue and Forecast, by Application
12.3.7.3. Market Revenue and Forecast, by Service Type
12.3.7.4. Market Revenue and Forecast, by End User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Vector Type
12.3.8.2. Market Revenue and Forecast, by Application
12.3.8.3. Market Revenue and Forecast, by Service Type
12.3.8.4. Market Revenue and Forecast, by End User
12.4. MEA
12.4.1. Market Revenue and Forecast, by Vector Type
12.4.2. Market Revenue and Forecast, by Application
12.4.3. Market Revenue and Forecast, by Service Type
12.4.4. Market Revenue and Forecast, by End User
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Vector Type
12.4.5.2. Market Revenue and Forecast, by Application
12.4.5.3. Market Revenue and Forecast, by Service Type
12.4.5.4. Market Revenue and Forecast, by End User
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Vector Type
12.4.6.2. Market Revenue and Forecast, by Application
12.4.6.3. Market Revenue and Forecast, by Service Type
12.4.6.4. Market Revenue and Forecast, by End User
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Vector Type
12.4.7.2. Market Revenue and Forecast, by Application
12.4.7.3. Market Revenue and Forecast, by Service Type
12.4.7.4. Market Revenue and Forecast, by End User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Vector Type
12.4.8.2. Market Revenue and Forecast, by Application
12.4.8.3. Market Revenue and Forecast, by Service Type
12.4.8.4. Market Revenue and Forecast, by End User
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Vector Type
12.5.2. Market Revenue and Forecast, by Application
12.5.3. Market Revenue and Forecast, by Service Type
12.5.4. Market Revenue and Forecast, by End User
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Vector Type
12.5.5.2. Market Revenue and Forecast, by Application
12.5.5.3. Market Revenue and Forecast, by Service Type
12.5.5.4. Market Revenue and Forecast, by End User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Vector Type
12.5.6.2. Market Revenue and Forecast, by Application
12.5.6.3. Market Revenue and Forecast, by Service Type
12.5.6.4. Market Revenue and Forecast, by End User
13.1. Charles River Laboratories
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Catalent Gene Therapy (Biodextris)
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Vigene Biosciences
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Lonza (Capsugel)
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. REGENXBIO
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Oxford Biomedica
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. GE Healthcare (Cytiva)
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. ICON plc
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Covance (Labcorp)
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Envigo (Inotiv)
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description